StocksFundsScreenerSectorsWatchlists
SWTX

SWTX - SpringWorks Therapeutics Inc Stock Price, Fair Value and News

50.72USD+0.62 (+1.24%)Delayed as of 28 Mar 2024, 11:58 am ET

Market Summary

SWTX
USD50.72+0.62
Delayedas of 28 Mar 2024, 11:58 am
1.24%

SWTX Alerts

  • 1 major insider sales recently.

SWTX Stock Price

View Fullscreen

SWTX RSI Chart

SWTX Valuation

Market Cap

3.7B

Price/Earnings (Trailing)

-11.37

Price/Sales (Trailing)

170.47

Price/Free Cashflow

-16.06

SWTX Price/Sales (Trailing)

SWTX Profitability

Return on Equity

-51.92%

Return on Assets

-44.79%

Free Cashflow Yield

-6.23%

SWTX Fundamentals

SWTX Revenue

Revenue (TTM)

21.7M

Rev. Growth (Yr)

20.11%

Rev. Growth (Qtr)

-1.04%

SWTX Earnings

Earnings (TTM)

-325.1M

Earnings Growth (Yr)

-27.16%

Earnings Growth (Qtr)

-18.74%

Breaking Down SWTX Revenue

52 Week Range

22.3452.06
(Low)(High)

Last 7 days

1.0%

Last 30 days

-3.0%

Last 90 days

42.6%

Trailing 12 Months

78.9%

How does SWTX drawdown profile look like?

SWTX Financial Health

Current Ratio

6.41

SWTX Investor Care

Shares Dilution (1Y)

18.06%

Diluted EPS (TTM)

-5.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202311.7M017.0M21.7M
20221.9M3.3M4.7M6.1M
202126.4M17.8M9.2M546.0K
2020002.2M35.0M
20190000

Tracking the Latest Insider Buys and Sells of SpringWorks Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 16, 2024
pichl daniel
sold
-751,550
50.1033
-15,000
chief people officer
Feb 16, 2024
pichl daniel
acquired
414,600
27.64
15,000
chief people officer
Feb 05, 2024
ashar bhavesh
sold
-238,435
49.3245
-4,834
chief commercial officer
Feb 02, 2024
ashar bhavesh
sold
-142,976
44.3749
-3,222
chief commercial officer
Feb 02, 2024
pichl daniel
sold
-1,160,360
44.3208
-26,181
chief people officer
Feb 02, 2024
pichl daniel
acquired
449,150
27.64
16,250
chief people officer
Jan 08, 2024
cassidy james
sold (taxes)
-45,392
41.53
-1,093
chief medical officer
Jan 08, 2024
ashar bhavesh
sold (taxes)
-60,177
41.53
-1,449
chief commercial officer
Jan 08, 2024
weinstein herschel s
sold (taxes)
-100,627
41.53
-2,423
general counsel & secretary
Jan 08, 2024
smith l. mary
sold (taxes)
-146,809
41.53
-3,535
chief development officer

1–10 of 50

Which funds bought or sold SWTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
added
180
791
1,022
-%
Mar 21, 2024
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
new
-
2,007,500
2,007,500
0.01%
Mar 13, 2024
MONECO Advisors, LLC
unchanged
-
238,860
651,598
0.12%
Mar 11, 2024
VANGUARD GROUP INC
added
22.63
106,526,000
220,334,000
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
55.71
19,975,000
33,673,100
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
added
14.7
545,178
1,217,530
-%
Feb 26, 2024
PERCEPTIVE ADVISORS LLC
added
28.73
36,287,500
71,439,500
1.59%
Feb 22, 2024
SIERRA SUMMIT ADVISORS LLC
new
-
256,303
256,303
0.07%
Feb 20, 2024
Quarry LP
reduced
-17.02
32,396
136,875
0.02%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
sold off
-100
-231
-
-%

1–10 of 43

Are Funds Buying or Selling SWTX?

Are funds buying SWTX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SWTX
No. of Funds

Unveiling SpringWorks Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
deep track capital, lp
5.53%
4,063,676
SC 13G/A
Feb 14, 2024
ecor1 capital, llc
0%
0
SC 13G/A
Feb 13, 2024
vanguard group inc
8.38%
6,036,542
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 26, 2024
blackrock inc.
7.5%
5,382,184
SC 13G/A
Jan 23, 2024
state street corp
3.64%
2,619,650
SC 13G/A
Dec 06, 2023
orbimed advisors llc
4.9%
3,567,159
SC 13D/A
May 17, 2023
orbimed advisors llc
6.7%
4,178,588
SC 13D/A
Apr 14, 2023
deep track capital, lp
5.21%
3,254,132
SC 13G
Mar 20, 2023
bc sw, lp
4.9%
3,081,307
SC 13D/A

Recent SEC filings of SpringWorks Therapeutics Inc

View All Filings
Date Filed Form Type Document
Mar 01, 2024
144
Notice of Insider Sale Intent
Feb 27, 2024
10-K
Annual Report
Feb 27, 2024
424B5
Prospectus Filed
Feb 27, 2024
8-K
Current Report
Feb 27, 2024
8-K
Current Report
Feb 27, 2024
S-8
Employee Benefits Plan
Feb 20, 2024
4
Insider Trading
Feb 16, 2024
144
Notice of Insider Sale Intent
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to SpringWorks Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

SpringWorks Therapeutics Inc News

Latest updates
InvestorsObserver • 47 hours ago
InvestorsObserver • 22 Mar 2024 • 04:22 pm
InvestorsObserver • 08 Mar 2024 • 08:00 am
Yahoo Finance • 07 Feb 2024 • 08:00 am
Investor's Business Daily • 4 months ago

SpringWorks Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22019Q32019Q2
Revenue-1.0%5,6035,6625,7564,66591237219818917921117,02833,84433.001579971,004
Operating Expenses-100.0%-83,99977,69978,45471,74069,01161,46955,79640,89547,02129,75623,78121,59219,82115,32914,851
  S&GA Expenses28.6%59,83646,54644,17540,52635,67330,98727,36626,45218,02914,93012,3818,5197,6696,8744,5843,646
  R&D Expenses16.6%43,65237,45333,52437,92836,06738,02434,10329,34422,86632,09117,37515,26213,92312,94710,74511,205
Interest Expenses----1,571---175---333----
Net Income-18.7%-94,322-79,437-73,420-74,178-72,388-69,050-61,801-56,072-41,041-47,010-29,78711,272-21,659-19,893-16,833-13,847
Net Income Margin16.5%-14.99*-17.94*-8.26*-7.93*-7.41*-6.51*-5.88*-4.97*-3.04*-2.49*-1.72*-----
Free Cashflow-11.7%-60,403-54,083-64,795-55,956-23,132-41,596-51,075-47,820-27,264-33,660-21,149-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32018Q4
Assets55.2%72646851756963068236640645249552055557628630131733534848.00
  Current Assets15.8%50143248453860065734235638343346748251327929431433134547.00
    Cash Equivalents78.1%17699.0011510267.0047770.0083.0010594.0085.0096.0014885.0022731232834446.00
  Inventory-3.00------------------
  Net PPE-14.2%18.0021.0018.0016.0014.0011.009.006.003.002.001.001.001.001.001.001.001.001.000.00
Liabilities36.9%10073.0066.0062.0072.0069.0040.0029.0030.0029.0024.0020.0019.0013.0010.009.0013.0011.005.00
  Current Liabilities55.5%78.0050.0042.0038.0051.0049.0035.0023.0030.0028.0023.0019.0018.0013.0010.009.0012.0010.004.00
Shareholder's Equity58.6%626395451507558612326377422467497535557273291308322337-
  Retained Earnings-11.8%-895-800-721-643-569-495-423-354-292-236-195-148-118-129-108-88.32-73.03-56.81-22.45
  Additional Paid-In Capital27.0%1,5241,2001,1771,1541,1301,1117527337157036926836764033993963953941.00
Shares Outstanding17.4%73.0063.0063.0063.0062.0050.0049.0049.0048.0048.0048.0048.00-------
Float---1,601---906---2,903---897----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-24.3%-62,705-50,461-47,811-61,818-54,200-19,604-39,071-48,688-46,316-26,929-33,528-21,10415,066-14,700-16,159-16,398-16,063-11,113-13,091-7,177-
  Share Based Compensation8.5%25,06723,09822,97423,39518,92418,51818,42917,09411,88210,7128,7957,0553,0423,0432,5991,350950788648723-
Cashflow From Investing-560.1%-159,20534,59960,75698,604-355,01086,23226,75726,42456,18135,78522,544-30,918-222,781-127,563-68,328-160-130-84.00-3,785-261-
Cashflow From Financing123683.1%299,071-242-342-1,848298340,231-88.00261244425129359269,97342878.006.0020.00169,731-163,957-
  Buy Backs-4.2%253264---212---------------

SWTX Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue:   
Total revenue$ 5,447$ 0$ 0
Operating expenses:   
Cost of product revenue42200
Research and development150,487146,122101,676
Selling, general and administrative197,551134,55271,792
Total operating expenses348,460280,674173,468
Loss from operations(343,013)(280,674)(173,468)
Interest and other income:   
Interest and other income, net22,9476,147546
Total interest and other income22,9476,147546
Equity method investment loss(5,038)(2,890)(988)
Net loss$ (325,104)$ (277,417)$ (173,910)
Net loss per share, basic (in usd per share)$ (5.15)$ (5.21)$ (3.59)
Net loss per share, diluted (in usd per share)$ (5.15)$ (5.21)$ (3.59)
Weighted average common shares outstanding, basic (in shares)63,123,93653,290,52848,497,790
Weighted average common shares outstanding, diluted (in shares)63,123,93653,290,52848,497,790
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]Product [Member]  

SWTX Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 176,053$ 67,490
Marketable securities303,149524,722
Accounts receivable, net5,9300
Inventory3,1030
Prepaid expenses and other current assets12,6777,548
Total current assets500,912599,760
Long-term marketable securities183,3864,794
Property and equipment, net17,94313,571
Operating lease right-of-use assets6,1444,698
Equity method investment1,9554,193
Restricted cash613578
Other assets14,8352,648
Total assets725,788630,242
Current liabilities:  
Accounts payable7,3968,010
Accrued expenses65,56939,242
Operating lease liabilities, current1,061483
Deferred revenue, current4,1443,314
Total current liabilities78,17051,049
Operating lease liabilities, long-term5,9964,768
Deferred revenue, long-term15,40316,233
Total liabilities99,56972,050
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding at December 31, 2023 and December 31, 2022.00
Common stock, $0.0001 par value, 150,000,000 shares authorized, 73,620,361 and 62,453,328 shares issued and 73,486,699 and 62,423,129 shares outstanding at December 31, 2023 and December 31, 2022, respectively.76
Additional paid-in capital1,524,1961,130,224
Accumulated deficit(895,034)(569,930)
Treasury stock, at cost (133,662 and 30,199 shares of common stock at December 31, 2023 and December 31, 2022, respectively).(4,141)(1,341)
Accumulated other comprehensive income (loss)1,191(767)
Total stockholders’ equity626,219558,192
Total liabilities and stockholders’ equity$ 725,788$ 630,242
SWTX
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.
 CEO
 WEBSITEwww.springworkstx.com
 EMPLOYEES227

SpringWorks Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for SpringWorks Therapeutics Inc? What does SWTX stand for in stocks?

SWTX is the stock ticker symbol of SpringWorks Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of SpringWorks Therapeutics Inc (SWTX)?

As of Wed Mar 27 2024, market cap of SpringWorks Therapeutics Inc is 3.7 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SWTX stock?

You can check SWTX's fair value in chart for subscribers.

What is the fair value of SWTX stock?

You can check SWTX's fair value in chart for subscribers. The fair value of SpringWorks Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of SpringWorks Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SWTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is SpringWorks Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether SWTX is over valued or under valued. Whether SpringWorks Therapeutics Inc is cheap or expensive depends on the assumptions which impact SpringWorks Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SWTX.

What is SpringWorks Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, SWTX's PE ratio (Price to Earnings) is -11.37 and Price to Sales (PS) ratio is 170.47. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SWTX PE ratio will change depending on the future growth rate expectations of investors.